Sanofi

Ask Sterling

Things you can ask Sterling:

Summarize Tesla's latest earnings reportWhy did NVIDIA's margins expand?Compare Apple vs Microsoft's cash flowWhat's driving the EV sector growth?

Favorites

Revenue Breakdown

Revenue Flow

Balance Sheet

Q3 2016-Q2 2026

Cash Flow

Q3 2016-Q2 2026

Sanofi

French pharma. Vaccines €7.936B in 2025: Beyfortus (infant RSV mAb with AstraZeneca), influenza, polio/pertussis/Hib, and travel/endemic. Agreed to acquire Dynavax in December 2025.

$SNYParis, France82,600sanofi.com

SectorsVaccines

Frequently asked questions

What does Sanofi do?

Sanofi (SNY) is a Drug Manufacturers - General company. French pharma. Vaccines €7.936B in 2025: Beyfortus (infant RSV mAb with AstraZeneca), influenza, polio/pertussis/Hib, and travel/endemic. Agreed to acquire Dynavax in December 2025. It was founded in 2004, is headquartered in Paris, France and employs about 82,600 people.

How has Sanofi's revenue and profitability trended?

Track Sanofi's quarterly and annual revenue, gross and net margins, and EPS in the interactive charts on this page. Data last updated August 19, 2026.

Who are Sanofi's main competitors?

Sterling groups Sanofi in the Vaccines sector, alongside GSK (GSK), Pfizer (PFE) and Merck & Co. (MRK).

If I'm investing in Sanofi, what similar companies should I consider?

If you are researching Sanofi, also look at GSK (GSK), Pfizer (PFE) and Merck & Co. (MRK). You can compare all of them side by side or browse the full Vaccines sector on Sterling.